Literature DB >> 26885096

Low expression of GNAI3 predicts poor prognosis in patients with HCC.

Guodong Chen1, Xiaoyan Li2, Gengsheng He3, Zijian Yu3, Jiaxing Luo3, Jun He3, Zonghai Huang4.   

Abstract

PURPOSES: This study was performed with an aim to explain the underlying role of GNAI3 on the prognosis of patients with HCC.
METHODS: The expression of GNAI3 at protein level was detected with the utilization of Immunohistochemistry (IHC). Chi-square test was conducted to assay the relationship between GNAI3 expression and clinical parameters of HCC patients. The correlation between expression level of GNAI3 and survival time after surgeries of HCC patients was evaluated by Kaplan-Meier method. Finally, the Cox regression was established to evaluate the relationship between GNAI3 expression and the prognosis of patients with HCC.
RESULTS: In this study, the negative rate of GNAI3 expression in HCC samples was about 76.6%, which was significantly higher than that in paired normal specimens (12.5%). Result showed that there was no correlation between GNAI3 expression and age, gender, liver cirrhosis and vein invasion (P>0.05), but tight relationship between GNAI3 expression and TNM stage and tumor size was found (P<0.05). The following Kaplan-Meier analysis result illustrated that negative expression of GNAI3 induced high mortality of HCC patients. Cox regression result revealed that GNAI3 might be a biomarker for prognosis of patients with HCC (HR: 0.218, P=0.016, 95% CI 0.063-0.750).
CONCLUSION: Generally, results of this study demonstrated that expression of GNAI3 shared a tight relationship with the prognosis of patients with HCC. Therefore, GNAI3 could be considered as a novel index for prognosis of patients with HCC.

Entities:  

Keywords:  GNAI3; HCC; prognosis

Year:  2015        PMID: 26885096      PMCID: PMC4723941     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  27 in total

1.  G proteins: more than transducers of receptor-generated signals?

Authors:  Stefan Engelhardt; Francesca Rochais
Journal:  Circ Res       Date:  2007-04-27       Impact factor: 17.367

2.  Liver transplantation for hepatocellular carcinoma in Puerto Ricans: underutilization of a curative therapy.

Authors:  Angel E Alsina; Ahmad Nakshabandi; Alexia M Makris; Esther A Torres
Journal:  P R Health Sci J       Date:  2014-12       Impact factor: 0.705

3.  Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes.

Authors:  Tan To Cheung; Kelvin K Ng; Kenneth S Chok; See Ching Chan; Ronnie T Poon; Chung Mau Lo; Sheung Tat Fan
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

4.  Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

Review 5.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 6.  Hepatocellular carcinoma: current management and future trends.

Authors:  Brian I Carr
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis.

Authors:  Patrick Kelly; Benjamin J Moeller; Juhi Juneja; Michelle A Booden; Channing J Der; Yehia Daaka; Mark W Dewhirst; Timothy A Fields; Patrick J Casey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-16       Impact factor: 11.205

Review 8.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

9.  Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients.

Authors:  Liliana S C Mendes; Marcelo E Nita; Suzane K Ono-Nita; Evandro S Mello; Luiz Caetano da Silva; Venancio A F Alves; Flair J Carrilho
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 10.  Thermal ablative therapy for malignant liver tumors: a critical appraisal.

Authors:  Kelvin Kwok-Chai Ng; Chi-Ming Lam; Ronnie Tung-Ping Poon; Victor Ai; Wai-Kuen Tso; Sheung-Tat Fan
Journal:  J Gastroenterol Hepatol       Date:  2003-06       Impact factor: 4.029

View more
  5 in total

1.  High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma.

Authors:  Jian-Dong Shen; Shou-Zhong Fu; Lin-Ling Ju; Yi-Fang Wang; Feng Dai; Zhao-Xiu Liu; Han-Zheng Ji; Jian-Guo Shao; Zhao-Lian Bian
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

2.  Downregulation of GNAI3 Promotes the Pathogenesis of Methionine/Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease.

Authors:  Hanzhang Zhu; Ke Ge; Jun Lu; Changku Jia
Journal:  Gut Liver       Date:  2020-07-15       Impact factor: 4.519

3.  Guanine and nucleotide binding protein 3 promotes odonto/osteogenic differentiation of apical papilla stem cells via JNK and ERK signaling pathways.

Authors:  Yang Zhang; Lichan Yuan; Li Meng; Mengru Fang; Shuyu Guo; Dongyue Wang; Junqing Ma; Lin Wang
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

4.  Identification of diagnostic long non‑coding RNA biomarkers in patients with hepatocellular carcinoma.

Authors:  Gang Li; Hao Shi; Xinyi Wang; Bei Wang; Qianqian Qu; Haiyang Geng; Hongjun Sun
Journal:  Mol Med Rep       Date:  2019-05-28       Impact factor: 2.952

5.  Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma.

Authors:  Jing Ye; Hui Liu; Zhi-Li Xu; Ling Zheng; Rong-Yu Liu
Journal:  J Clin Lab Anal       Date:  2019-08-11       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.